Usman Baber to Fibrinolytic Agents
This is a "connection" page, showing publications Usman Baber has written about Fibrinolytic Agents.
Connection Strength
1.271
-
Acute coronary syndromes: Antithrombotics in ACS--moving beyond unfractionated heparin. Nat Rev Cardiol. 2011 Sep 27; 8(11):613-4.
Score: 0.372
-
Antithrombotic strategy variability in atrial fibrillation and obstructive coronary disease revascularised with percutaneous coronary intervention: primary results from the AVIATOR 2 international registry. EuroIntervention. 2022 Oct 07; 18(8):e656-e665.
Score: 0.200
-
Limitations of Current Risk Scoring in Real World Populations: The Importance of External Validation. Rev Esp Cardiol (Engl Ed). 2019 Mar; 72(3):192-194.
Score: 0.152
-
Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nat Rev Cardiol. 2018 08; 15(8):480-496.
Score: 0.150
-
Antithrombotic potency of ticagrelor versus clopidogrel in type-2 diabetic patients with cardiovascular disease. Thromb Haemost. 2017 10 05; 117(10):1981-1988.
Score: 0.140
-
Patients with chronic kidney disease/diabetes mellitus: the high-risk profile in acute coronary syndrome. Curr Cardiol Rep. 2013 Aug; 15(8):386.
Score: 0.106
-
How serious a problem is bleeding in patients with acute coronary syndromes? Curr Cardiol Rep. 2011 Aug; 13(4):312-9.
Score: 0.092
-
Effect of valve design and anticoagulation strategy on 30-day clinical outcomes in transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. Catheter Cardiovasc Interv. 2017 Nov 15; 90(6):1016-1026.
Score: 0.035
-
Prognostic significance of elevated baseline troponin in patients with acute coronary syndromes and chronic kidney disease treated with different antithrombotic regimens: a substudy from the ACUITY trial. Circ Cardiovasc Interv. 2012 Apr; 5(2):157-65.
Score: 0.024